Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2024-09-12 00:00:00 ET · period of report 2024-09-10 · accession 0001140361-24-040989 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-12 | 2024-09-10 | ROIV | Gold Daniel Allen | Dir | A - Grant | $0.00 | +16.4K | 7.29M | +0.2% | $0 |
| D | 2024-09-12 | 2024-09-10 | ROIV | Gold Daniel Allen | Dir | A - Grant | $0.00 | +27.9K | 27.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-09-10 | A | A | 16,406 | $0.00 | 7,291,692 | D | — | — | (F1) Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-09-10 | A | A | 27,894 | $0.00 | 27,894 | D | $12.19 · — to 2034-09-09 | 27,894 Common Shares | (F3) Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. |